rifampin and pixantrone

rifampin has been researched along with pixantrone* in 1 studies

Other Studies

1 other study(ies) available for rifampin and pixantrone

ArticleYear
Pixantrone Sensitizes Gram-Negative Pathogens to Rifampin.
    Microbiology spectrum, 2022, 12-21, Volume: 10, Issue:6

    The emergence of bacterial drug resistance poses a severe threat to global public health. In particular, antimicrobial-resistant pathogens lead to a high rate of treatment failure and significantly increase mortality. Repurposing FDA-approved compounds to sensitize superbugs to conventional antibiotics provides a promising strategy to alleviate such crises. Pixantrone (PIX) has been approved for treating aggressive B-cell non-Hodgkin's lymphoma. By high-throughput drug screening, we profiled the synergistic activity between PIX and rifampin (RFP) against Gram-negative extensively drug-resistant isolates by checkerboard assay. Mechanistic studies demonstrated that PIX impacted the flagellum assembly, induced irreversible intracellular reactive oxygen species accumulation and disrupted proton motive force. In addition, the combination of PIX with RFP possesses effective antimicrobial activity against multidrug-resistant strains

    Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Isoquinolines; Microbial Sensitivity Tests; Rifampin

2022